The promise of immunotherapy has shone brightly for decades in hematologic malignancies and specifically in non-Hodgkin lymphoma. The last decade has witnessed the emergence of completely novel forms of immunotherapy, including immune checkpoint blockade, bispecific antibodies, and chimeric antigen receptor T cells. These treatments have shown phenomenal, and in some cases possibly curative, successes in various relapsed/refractory lymphomas. This review summarizes the most notable successes and promising findings as well as some of the attendant failures. These treatments will doubtlessly transform the treatment paradigms across many lymphoma subtypes. Yet, only if we can better understand their mechanisms of action, toxicity, and resistance will be able to maximize their therapeutic benefit.

免疫疗法的前景在血液系统恶性肿瘤，特别是非霍奇金淋巴瘤中已有数十年的辉煌历史。过去十年见证了全新形式的免疫疗法的出现，包括免疫检查点阻断，双特异性抗体和嵌合抗原受体T细胞。这些治疗方法已在各种复发/难治性淋巴瘤中取得了惊人的成功，在某些情况下甚至可以治愈。这篇综述总结了最显着的成功和有希望的发现，以及一些随之而来的失败。这些治疗无疑会改变许多淋巴瘤亚型的治疗模式。但是，只有我们能够更好地了解它们的作用机理，毒性和耐药性，才能使它们的治疗益处最大化。